A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

This study is testing a new drug called SHR-1501, alone or combined with BCG (an existing bladder cancer treatment) or SHR-1316 (another immune drug), for people with non-muscle-invasive bladder cancer (NMIBC) that is high risk. These are bladder tumors that haven't grown into the muscle wall yet but have a high chance of coming back. **You may be eligible if...** - You are 18 or older - You have been diagnosed with high-risk NMIBC confirmed by biopsy - A recent cystoscopy (within 6 weeks) showed the tumor has been fully removed or only carcinoma in situ remains - Your general health is good (ECOG score 0–2) - Your expected survival is at least 2 years **You may NOT be eligible if...** - Your cancer has grown into or beyond the muscle of the bladder wall - You have already received certain immunotherapy treatments - Your organ function is not adequate Talk to your doctor to see if this trial is right for you.